GLP-1s, Pregnancy and Birth Control: What the Labels Require

5 min read · doses off DailyMed · last verified October 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The semaglutide labels say to come off the drug at least two months ahead of a planned pregnancy, and the weight-loss labels want the drug stopped as soon as a pregnancy is known. Animal studies show harm to the fetus and the human evidence is thin. Several also warn that a slowed stomach can interfere with how well the contraceptive pill is absorbed. That warning is the one most likely to matter to someone who is not planning a pregnancy.

Stopping before conception

Stopping before conception
DrugRoughly how long it lingersWhat the label asks
Wegovy / Ozempic (semaglutide)About a weekStop a full two months ahead of a planned pregnancy. This is the one written explicitly into a label.
Zepbound / Mounjaro (tirzepatide)About five daysZepbound: stop as soon as a pregnancy is known about. Mounjaro, for diabetes: the label leaves pregnancy use to a weighing of benefit against fetal risk.
Saxenda (liraglutide)About 13 hoursStop when pregnancy is recognized. Clears in days rather than months, but still plan it with your prescriber.
Foundayo (orforglipron)About one to two daysStop when pregnancy is recognized; discuss any plan beforehand.

The two-month figure for semaglutide reflects how long the drug takes to clear after a final dose. The other rows are reference points, not rules, and the decision belongs with your prescriber, ideally alongside a maternal-fetal medicine specialist.

The contraception warning people miss

The Zepbound label tells anyone relying on the contraceptive pill to move onto a method that is not swallowed, or to pair it with a barrier method, across four weeks from the start and four weeks from each increase thereafter.

The second half is the part people miss. On a ladder with five increases, that is five separate four-week stretches when the pill alone may not be doing what you think it is. It is easy to hear the warning once, at the start, and never apply it again.

  • Why: these drugs slow the stomach, and the effect is sharpest right after starting and right after each step up, which is when absorption of a swallowed tablet is least predictable.
  • What sidesteps it entirely: any method that is not swallowed: an IUD, an implant, the injection, the patch or the ring.
  • This comes from the label. Ask your prescriber which method suits you while you are titrating.

If you are already pregnant

  1. Do not panic. The labels say to stop. None of them describes an exposure as grounds for ending a pregnancy, and findings in animals do not transfer one-to-one to people.
  2. Write down the timeline: date of last injection, the dose, how many weeks along you were, and anything else you take. That is what the specialist team needs.
  3. Stop the GLP-1. Carry on with prenatal vitamins, folate and everything obstetric.
  4. Ask for a maternal-fetal medicine referral. Counseling and any extra scanning happen there rather than in primary care.
  5. Consider the manufacturers' pregnancy registries. They enroll exposed pregnancies specifically to build the human record that does not yet exist. Your exposure could inform the advice given to someone else.

Breastfeeding

The labels split by product. The semaglutide tablets (Rybelsus, Ozempic tablets, the Wegovy pill) and Foundayo advise against breastfeeding; the injectables leave it to a weighing of benefit against need. Two labels report a human milk study. Tirzepatide was undetectable in almost every sample, and semaglutide from the tablets stayed below the level the test could measure, although the tablets' absorption enhancer (SNAC) does reach milk. No label has any data on milk supply. The drug-by-drug detail is in GLP-1s while breastfeeding.

That makes it a judgment call, and one to make with both your prescriber and a lactation specialist.

The unplanned pregnancies

Most surprise conceptions on these drugs have a plain explanation: weight loss, mostly, rather than any direct effect of the drug on ovulation.

In polycystic ovary syndrome, losing 5 to 10% of your body weight restores ovulation in a meaningful share of people, and losing 5 to 10% is what these drugs reliably do. Someone who had not been ovulating, and therefore had not needed contraception, may now need it. Layer the pill-absorption issue on top and the two effects compound.

If you have PCOS and are starting one of these drugs, talk to your prescriber about contraception before you start.

Call the specialist team if

  • A pregnancy test is positive while you are on the drug. Stop it and call your prescriber the same day.
  • Severe sickness in early pregnancy after recent exposure. Hyperemesis plus a drug that slows the stomach needs to be seen in person, not handled by message.
  • Bleeding, severe abdominal pain, or dehydration in any exposed pregnancy.
  • Anything unexpected on a first-trimester screen or anatomy scan where there was exposure. Route that to maternal-fetal medicine.
  • You are breastfeeding and someone wants to restart the drug. That needs both your prescriber and a lactation specialist.

What this does not cover

  • Fertility treatment. IVF and IUI clinics set their own washout windows and they are often stricter than the insert. Ask that team directly.
  • Compounded GLP-1s, which have no pregnancy or lactation data whatsoever. Applying a brand label's data to them is guesswork.
  • Managing diabetes in pregnancy, which belongs with endocrinology and maternal-fetal medicine.

Where to go next

References

  1. 1.U.S. National Library of Medicine — DailyMed. WEGOVY (semaglutide) injection — Structured Product Label (pregnancy + contraception sections). DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. 2.U.S. National Library of Medicine — DailyMed. OZEMPIC (semaglutide) injection — Structured Product Label (pregnancy + contraception sections). DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  3. 3.U.S. National Library of Medicine — DailyMed. ZEPBOUND (tirzepatide) injection — Structured Product Label (pregnancy + contraception sections). DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  4. 4.U.S. National Library of Medicine — DailyMed. MOUNJARO (tirzepatide) injection — Structured Product Label (pregnancy + contraception sections). DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  5. 5.U.S. National Library of Medicine — DailyMed. RYBELSUS / OZEMPIC (semaglutide) tablets — Structured Product Label (lactation + pregnancy sections). DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
  6. 6.U.S. National Library of Medicine — DailyMed. SAXENDA (liraglutide) injection — Structured Product Label (pregnancy + pharmacokinetics sections). DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
  7. 7.U.S. National Library of Medicine — DailyMed. FOUNDAYO (orforglipron) tablets — Structured Product Label (pregnancy + lactation sections). DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62

Frequently Asked Questions

At least two months, and this one is written into the label rather than inferred from the half-life. Semaglutide takes considerable time to clear after a final dose, and the two-month figure reflects that. Tirzepatide, liraglutide and orforglipron all clear faster, and the Zepbound, Saxenda and Foundayo labels just say to come off the drug when pregnancy is confirmed. Planning a pregnancy on any of them is still a conversation to have with your prescriber.
Stop the drug and call your prescriber, but do not panic. No label treats an exposure as grounds for ending a pregnancy, and animal findings do not map directly onto people. Write down when your last dose was, at what dose, and how far along you were, then ask for a maternal-fetal medicine referral. Enrolling in the manufacturer's pregnancy registry is worth considering, because the human safety record is still being built.
They can, and the label is specific about when. Zepbound asks pill users to move to a method that is not swallowed, or to pair the pill with a barrier method, across four weeks from the start and four from each increase. On a six-step ladder that means five separate windows, not just one at the beginning. An IUD, implant, injection, patch or ring is not swallowed, so it is unaffected.
The data are thin and differ by drug. For injected semaglutide the labels have no data on presence in human milk, on the infant or on supply; semaglutide turned up in rat milk, which is why the wording is cautious. For tirzepatide, a single-dose study in 11 breastfeeding women found it undetectable or low in milk, but there are no data on the infant or on supply. The semaglutide tablets are a separate case, and their labels advise against breastfeeding. It is a judgment call to make with your prescriber and a lactation specialist rather than from any general guidance.
Mostly because of the weight loss rather than any direct effect on ovulation. In polycystic ovary syndrome, ovulation that had stopped or become irregular can return as weight comes down, and weight loss is what these drugs deliver. Someone who was not ovulating may not have needed contraception before and does now. If the method they reach for is the pill, the absorption warning applies at the same time.

Editorial reference content, not medical advice. Changing a dose, holding one, or stopping altogether is a decision for you and your prescriber together. As for the numbers: we checked every dose figure here against the FDA-approved Structured Product Label on DailyMed in October 2026.

Browse all cheat sheets, top-N research lists, or long-form research deep-dives.